AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that each of the securities class action lawsuits filed against the Company and certain of its officers and directors, has been dismissed. The lawsuits had been consolidated and recently transferred to federal court in Georgia. The plaintiffs agreed to dismiss the matters voluntarily, without prejudice, and without any payment or consideration to the plaintiffs or their counsel.
